Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Schering Sales Force Recruitment Is 80% Complete; Morale Remains High

Feb 02 2004

• By The Pink Sheet

Related Content

Schering Reinvesting In Sales After Cutbacks; “Selective” Support For Zetia

Jul 28 2003

Pegasys Catching Up To PEG-Intron; Schering Admits “Complacency”

Aug 04 2003

Ribavirin ANDAs Await ICN Petition; FDA Generic Rule Takes Effect

Aug 18 2003

Schering Stabilizes Market Share Losses With Revamped Sales Effort

Nov 24 2003

Allegra Managed Care Talks Ongoing: Aventis Expects No “Major Shifts”

Nov 03 2003

Merck/Schering Zetia Early Use Is In High-Risk Patients; New Rx Share At 5%

Nov 03 2003

The 10% Solution: Roche Cuts U.S. Sales Force, Schering Reduces Payroll

Dec 08 2003

Aventis Sees “Blurring” Of Rx/OTC Distinctions; Change Coming For Allegra?

Jan 19 2004

Schering Sales Force Reduction Shows “Changing Dynamics” In U.S. Market

Jul 01 2002

Schering Rebetol Is Only “Medically Necessary” Oral Product In FDA Decree

May 27 2002

Schering/Merck Zetia Clears FDA; Price Favors Combo With Low-Dose Zocor

Nov 04 2002

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window